Introduction
There is increasing use of neoadjuvant chemotherapy (NAC) in the management of early-stage breast cancer [1] . On the basis of the importance of angiogenesis in breast cancer progression [2] and promising results from early studies of bevacizumab, a monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A, in metastatic breast cancer [3] , multiple clinical trials in the neoadjuvant setting were conducted. Four of these trials have reported results, including NSBAP B-40 [4, 5] , GeparQuinto [6, 7] , CALGB 40603 [8] , and the ARTemis trial [9] .
Achievement of a pathological complete response (pCR), with complete eradication of invasive breast cancer in the breast and nodes, has been associated with improved Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.pharmacogeneticsandgenomics.com. survival, with the greatest prognostic value in aggressive tumor subtypes [10] . We hypothesized that there are genes related to the achievement of a pCR in women treated with NAC, with or without bevacizumab, and that we would be able to identify germ-line genetic variation measured as single nucleotide polymorphisms (SNPs) associated with pCR, with a genome-wide association study (GWAS) utilizing B-40 [4] and attempting replication with HER2-negative patients entered on GeparQuinto [6] .
Methods

Source of patients
All patients with HER2-negative early breast cancer entered on NSABP B-40 (Schema: Supplementary Fig. 1 , Supplemental digital content 1, http://links.lww.com/FPC/ B312) with a blood sample for DNA extraction and consent for genetic testing were eligible following Mayo IRB review.
Definition of phenotype
The pCR definition was the complete eradication of all invasive breast cancer in both the breast and regional nodes.
Study design
Anonymized samples were sent to Mayo Clinic for DNA extraction, were plated, and sent to the RIKEN Center for Integrative Medical Science for genotyping. The clinical and genotyping data were then analyzed at Mayo Clinic. The primary objective was to identify genetic variation measured as SNPs associated with pCR with a GWAS. Secondary objectives were to explore the association of SNPs with outcomes, that is, disease-free survival (DFS) and overall survival (OS). An ad-hoc exploratory GWAS was performed with the phenotype of pCR in patients randomized to bevacizumab.
Genotyping, quality control, and imputation
Genotyping was performed with the Illumina HumanOmniExpressExome BeadChips. Details with regard to genotyping, quality control, and imputation are given in the Supplementary Material (Supplemental digital content 2, http://links.lww.com/FPC/B313).
The data from this GWAS have been deposited in the Data Base of Genotypes and Phenotypes. The Data Base of Genotypes and Phenotypes Study Accession Number is phs001365.v1.p1 (https://www.ncbi.nlm.nih.gov/projects/gapprev/ gap/cgi-bin/preview1.cgi?GAP_phs_code=DlBPhGnsRxXYbJZW).
Statistical analysis
The primary analyses were based on logistic regression with SNP genotypes analyzed as log-additive effects on the chance of a pCR. The primary covariates that were adjusted for include treatment arm and any other clinical factors found to be associated with pCR (P < 0.10). To control for potential population stratification, we used the program STRUCTURE and HapMap racial groups to determine additional covariates. We utilized EigenStrat to determine the eigen values for the SNP correlation matrix that statistically differed from 0 [11, 12] . To evaluate the association of SNPs with DFS and OS, we used the Cox proportional hazards model, including covariates to adjust for patient heterogeneity.
Replication
Replication of top SNPs from the four GWAS (pCR, DFS, OS, and pCR in bevacizumab patients) was attempted utilizing genotyping data from patients with HER2-negative early breast cancer entered on GeparQuinto (Schema: Supplementary Fig. 2 , Supplemental digital content 1, http://links.lww.com/FPC/ B312, Supplementary Table, Supplemental digital content 2, http://links.lww.com/FPC/B313). Details with regard to genotyping, quality control, imputation, and sample cohorts for individual GWAS of GeparQuinto are given in the Supplementary Material (Supplemental digital content 2, http://links.lww.com/FPC/B313).
Results
Patients studied
The participant flow diagram ( Supplementary Fig. 3 , Supplemental digital content 1, http://links.lww.com/FPC/ B312) shows the B-40 patients included and excluded from the four GWAS with the phenotypes of (a) pCR, (b) DFS, (c) OS, and (d) pCR in bevacizumab-treated patients only. Supplementary Fig. 4 (Supplemental digital content 1, http://links.lww.com/FPC/B312) shows the GeparQuinto patients included in the replication studies.
Genome-wide association study with phenotype of pathological complete response Table 1 shows the clinical summary of the 914 patients in the primary analysis. The analysis was adjusted for treatment (bevacizumab, no bevacizumab), race, completion of NAC, and tumor grade, in addition to being stratified for categorical-age, estrogen receptor/ progesterone receptor status, tumor size and nodal stage. The distribution of P values is shown in the Manhattan plot (Fig. 1a) and locus zoom ( Supplementary Fig. 5A , Supplemental digital content 1, http://links.lww.com/FPC/ B312), and it revealed the top SNP (rs34843881, imputed) on chromosome 13 to have a P-value of 2.04E − 07, which did not reach genome-wide statistical significance ( Table 2 ). The quantile-quantile (QQ) plot for the conditional logistic regression results is shown in Supplementary Fig. 6A (Supplemental digital content 1, http://links.lww.com/FPC/B312). The top SNP was examined in GeparQuinto and showed P = 0.73 (Table 2) , indicating this was not an important signal.
Genome-wide association study with phenotype of disease-free survival
The GWAS with the phenotype of DFS was performed with 890 patients, as 24 of the 914 patients were removed because of missing outcome data and/or tumor grade. A DFS event occurred in 219 (24.6%) of the patients.
Stepwise analysis showed that clinical variables such as treatment, tumor grade, and completion of NAC were associated with DFS, and these variables were controlled for in the analysis, in addition to race. The Manhattan plot (Fig. 1b) and locus zoom (Supplementary Fig. 5B , Supplemental digital content 1, http://links.lww.com/FPC/ B312) revealed the top SNP (rs78269823, imputed) on chromosome 14 to have a P-value of 5.61E − 08, which approached but did not reach genome-wide significance. The QQ plot is shown in Supplementary Fig. 6B , (Supplemental digital content 1, http://links.lww.com/FPC/ B312). The top SNP was examined in GeparQuinto and showed P = 0.76 (Table 2) , indicating this was not an important signal.
Genome-wide association study with phenotype of overall survival
The GWAS with the phenotype of OS was performed with 891 patients of whom 144 (16.1%) had died. The model was controlled by the same variables as for DFS. The Manhattan plot (Fig. 1c) and locus zoom (Supplementary Fig. 5C , Supplemental digital content 1, http://links.lww.com/FPC/ B312) revealed the top SNP (rs56330643, imputed) on chromosome 14 to have a P-value of 5.63E − 08, which approached but did not reach genome-wide significance. The QQ-plot is shown in Supplementary Fig. 6C (Supplemental digital content 1, http://links.lww.com/FPC/ B312). The top SNP was examined in GeparQuinto and showed P = 0.50 (Table 2) , indicating this was not an important signal.
Exploratory genome-wide association study in patients who received bevacizumab
The GWAS with the phenotype of pCR was performed with 447 patients who had received bevacizumab of whom 147 (32.8%) had achieved a pCR. The model was controlled for the stratification variables noted above, race, and tumor grade. The Manhattan plot (Fig. 1d ) and locus zoom ( Supplementary Fig. 5D , Supplemental digital content 1, http://links.lww.com/FPC/B312) revealed the top SNP (rs7453577, imputed) to have a P-value of 2.97E − 07. The QQ plot is shown in Supplementary  Fig. 6D (Supplemental digital content 1, http://links.lww. com/FPC/B312). The top SNP was examined in GeparQuinto and showed P = 0.04 (Table 2) , which achieved statistical significance.
Given the findings from GeparQuinto, we examined this area more closely. In the B-40 GWAS, there were a total of 17 SNPs in addition to the top SNP in a gene, CDKAL1 (CDK5 Regulatory Subunit Associated Protein 1 Like 1), with P values ranging from 3.11E − 07 to 8.63E − 07. Included in these SNPs was a single genotyped SNP, rs1004172, with P = 3.73E − 07. The MAFs of these SNPs were 0.19-0.22.
Discussion
The primary objective of this study was to identify any association between germ-line genetic variation and pCR in women receiving NAC in B-40. The top SNP (rs34843881) did not achieve genome-wide significance (P = 2.04 E − 07). When this SNP was examined in the GeparQuinto database, there was no evidence of any association (P = 0.73).
Secondary objectives were to identify any association between germ-line genetic variation and the outcomes of DFS and OS in women receiving NAC. The top SNPs from B-40 almost reached genome-wide significance, P-value accepted to be 5E − 08, that is, 5.61E − 08 and 5.63E − 08, respectively. However, when examined in GeparQuinto, the P values were not replicated, being P = 0.76 and 0.50, respectively.
Because those studies reported a significantly higher pCR rate in the patients randomized to bevacizumab, we performed an exploratory GWAS only in the patients who received bevacizumab. The top SNP (rs7453577) had a P-value of 2.97E − 07 in B-40 and, when examined in GeparQuinto, was significant (P = 0.04). Given that this was an ad-hoc analysis, it must be considered hypothesis generating. The top SNP was located in CDKAL1, which encodes a protein that is a member of the methylthiotransferase family. The function of this gene is not known, but prior GWAS have linked SNPs in an intron of CDKAL1, with susceptibility to type II diabetes [13] .
Ideally, a replication study should be identical to a discovery study. Although B-40 and GeparQuinto have substantial similarities, they also have differences. The anthracycline utilized was different, being doxorubicin in B-40 and epirubicin in GeparQuinto. The sequencing of the anthracycline and taxane was opposite, and the duration of bevacizumab therapy was different in the two studies. Patients were taken off study if a response was not seen after the four cycles of the anthracycline plus cyclophosphamide in the GeparQuinto study. Moreover, in B-40, bevacizumab had a significantly higher pCR rate in ER-positive patients, whereas in GeparQuinto, the bevacizumab had a significantly higher pCR rate in ER-negative patients. These differences demonstrate that, in pharmacogenomics, the identification of an ideal replication study can be difficult.
Conclusion
We performed GWAS in a major NAC study and did not find a significant association between germ-line genetic variation and pCR, DFS, or OS. The observation of an SNP in CDKAL1 associated with pCR in the bevacizumab arm of both B-40 and GeparQuinto requires further validation and study. Table 2 Top single nucleotide polymorphism from the genome-wide association studies for pathological complete response, disease-free survival, overall survival, and bevacizumab-treated patients with replication utilizing GeparQuinto CA, common allele; CHR, chromosome; DFS, disease-free survival; lci, lower 95% confidence interval; MA, minor allele; MAF, minor allele frequency; OR, odds ratio; OS, overall survival; pCR, pathological complete response; POS, position; rsID, reference sequence ID; uci, upper 95% confidence interval.
